MedTrace Logo

Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis

NCT05016284 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-12-19

No results posted yet for this study

Summary

To compare the efficacy of a JW-100 cream with active control (commercially available as EUCRISA®, Pfizer) for the treatment of atopic dermatitis (AD) in adult patients with mild to moderate AD measured with the Investigator's Static Global Assessment (ISGA) scale.

Conditions

Interventions

OTHER

JW-100

Cosmetic CBD cream (JW-100)

DRUG

Eucrisa

Topical EUCRISA®, Pfizer

Sponsors & Collaborators

  • Jupiter Wellness, Inc.

    collaborator UNKNOWN

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel Fonseca, MD · Hospital Samel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-24
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05016284 on ClinicalTrials.gov